Verge Genomics utilizes a proprietary all-in-human, AI-powered drug discovery platform that integrates machine learning with a large multi-omics database derived from human tissue. The company focuses on developing effective treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis, by rapidly translating insights from human biology into drug candidates.
Funding
$134.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Traditional drug discovery methods often rely on animal or cell models that do not accurately replicate human biology, leading to high failure rates in clinical trials. This is particularly challenging in neurodegenerative diseases, where the complexity of the human brain makes it difficult to translate findings from preclinical studies to effective treatments.
Solution
Verge Genomics utilizes an all-in-human, AI-powered drug discovery platform that integrates machine learning with a large multi-omics database derived directly from human tissue. This approach allows the company to rapidly translate insights from human biology into drug candidates, focusing on developing effective treatments for neurodegenerative diseases. By starting with human data, Verge Genomics aims to improve the success rate of drug development and address unmet medical needs in diseases like amyotrophic lateral sclerosis (ALS), Parkinson's Disease, and Frontotemporal Dementia.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as ALS, Parkinson's Disease, and Frontotemporal Dementia, as well as pharmaceutical companies seeking innovative drug discovery platforms and novel drug candidates.
Features
- Proprietary multi-omics database built directly from human tissue samples
- CONVERGE®: AI-powered platform that maps the complex causes of disease
- Internal biology and chemistry platforms for developing proprietary drug candidates
- Focus on small molecule inhibitors for neurodegenerative diseases
- Rapid translation from research to clinic, exemplified by VRG50635 for ALS